Sofosbuvir; Velpatasvir; Voxilaprevir Patent Expiration

Sofosbuvir; Velpatasvir; Voxilaprevir is Used for treating chronic HCV infection in adults who have been previously treated with specific medications. It was first introduced by Gilead Sciences Inc in its drug Vosevi on Jul 18, 2017.


Sofosbuvir; Velpatasvir; Voxilaprevir Patents

Given below is the list of patents protecting Sofosbuvir; Velpatasvir; Voxilaprevir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vosevi US11338007

(Pediatric)

Combination formulation of three antiviral compounds Dec 01, 2037 Gilead Sciences Inc
Vosevi US10912814 Combination formulation of three antiviral compounds Jun 01, 2037 Gilead Sciences Inc
Vosevi US11338007 Combination formulation of three antiviral compounds Jun 01, 2037 Gilead Sciences Inc
Vosevi US11116783

(Pediatric)

Combination formulation of two antiviral compounds Jul 30, 2034 Gilead Sciences Inc
Vosevi US9296782 Inhibitors of hepatitis C virus Jul 17, 2034 Gilead Sciences Inc
Vosevi US11116783 Combination formulation of two antiviral compounds Jan 30, 2034 Gilead Sciences Inc
Vosevi US8575135

(Pediatric)

Antiviral compounds May 16, 2033 Gilead Sciences Inc
Vosevi US8921341

(Pediatric)

Antiviral compounds May 16, 2033 Gilead Sciences Inc
Vosevi US8940718

(Pediatric)

Antiviral compounds May 16, 2033 Gilead Sciences Inc
Vosevi US8575135 Antiviral compounds Nov 16, 2032 Gilead Sciences Inc
Vosevi US8921341 Antiviral compounds Nov 16, 2032 Gilead Sciences Inc
Vosevi US8940718 Antiviral compounds Nov 16, 2032 Gilead Sciences Inc
Vosevi US9868745 Antiviral compounds Nov 16, 2032 Gilead Sciences Inc
Vosevi US8618076

(Pediatric)

Nucleoside phosphoramidates Jun 11, 2031 Gilead Sciences Inc
Vosevi US9284342

(Pediatric)

Nucleoside phosphoramidates Mar 13, 2031 Gilead Sciences Inc
Vosevi US8618076 Nucleoside phosphoramidates Dec 11, 2030 Gilead Sciences Inc
Vosevi US9284342 Nucleoside phosphoramidates Sep 13, 2030 Gilead Sciences Inc
Vosevi US7964580

(Pediatric)

NA Sep 26, 2029 Gilead Sciences Inc
Vosevi US8633309

(Pediatric)

Nucleoside phosphoramidates Sep 26, 2029 Gilead Sciences Inc
Vosevi US8889159

(Pediatric)

Compositions and methods for treating hepatitis C virus Sep 26, 2029 Gilead Sciences Inc
Vosevi US7964580 NA Mar 26, 2029 Gilead Sciences Inc
Vosevi US8633309 Nucleoside phosphoramidates Mar 26, 2029 Gilead Sciences Inc
Vosevi US8889159 Compositions and methods for treating hepatitis C virus Mar 26, 2029 Gilead Sciences Inc
Vosevi US8334270

(Pediatric)

NA Sep 21, 2028 Gilead Sciences Inc
Vosevi US8580765

(Pediatric)

NA Sep 21, 2028 Gilead Sciences Inc
Vosevi US8735372

(Pediatric)

NA Sep 21, 2028 Gilead Sciences Inc
Vosevi US9085573

(Pediatric)

NA Sep 21, 2028 Gilead Sciences Inc
Vosevi US8334270 NA Mar 21, 2028 Gilead Sciences Inc
Vosevi US8580765 NA Mar 21, 2028 Gilead Sciences Inc
Vosevi US8735372 NA Mar 21, 2028 Gilead Sciences Inc
Vosevi US8957046 NA Mar 21, 2028 Gilead Sciences Inc
Vosevi US9085573 NA Mar 21, 2028 Gilead Sciences Inc
Vosevi US9585906 NA Mar 21, 2028 Gilead Sciences Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sofosbuvir; Velpatasvir; Voxilaprevir's patents.

Given below is the list recent legal activities going on the following patents of Sofosbuvir; Velpatasvir; Voxilaprevir.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 13 Sep, 2023 US9296782
Payment of Maintenance Fee, 8th Year, Large Entity 03 Aug, 2022 US8957046
Post Issue Communication - Certificate of Correction 21 Jun, 2022 US11338007
Recordation of Patent Grant Mailed 24 May, 2022 US11338007
Patent Issue Date Used in PTA Calculation 24 May, 2022 US11338007
Email Notification 05 May, 2022 US11338007
Issue Notification Mailed 04 May, 2022 US11338007
Email Notification 28 Apr, 2022 US11338007
Mailing Corrected Notice of Allowability 28 Apr, 2022 US11338007
Corrected Notice of Allowability 22 Apr, 2022 US11338007


Sofosbuvir; Velpatasvir; Voxilaprevir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List